The very favorable metastatic renal cell carcinoma (mRCC) risk group: Data from the International Metastatic RCC Database Consortium (IMDC).
Andrew Schmidt(Dana-Farber Cancer Institute), Toni K. Choueiri(Harvard University), Camillo Porta(University of Pavia), Aaron R. Hansen(Princess Margaret Cancer Centre), Ziad Bakouny(Dana-Farber Cancer Institute), Benoit Beuselinck(Universitair Ziekenhuis Leuven), Connor Wells(Queen Mary University of London), Ben Tran(The Royal Melbourne Hospital), Bernadett Szabados(Queen Mary University of London), Frede Donskov(Aarhus University Hospital), Georg A. Bjarnason(Sunnybrook Health Science Centre), Wanling Xie(Dana-Farber Cancer Institute), Lori Wood(Dalhousie University), Cristina Suárez(Complejo Hospitalario de Salamanca), Takeshi Yuasa(Japanese Foundation For Cancer Research), Shaan Dudani(William Osler Health System), Neeraj Agarwal(University of Utah), Chun Loo Gan(University of Calgary), Daniel Yick Chin Heng(University of Calgary), José Manuel Ruiz Morales(Hospital Médica Sur)
Cited by 13
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma
|Nature Medicine|2020|1k
The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma
|Cancer Cell|2014|867